Response to: 'Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?' by Yamashita et al

Pouletty M, Dingulu G, Ouldali N, Corseri O, Ducrocq C, Meinzer U, Faye A, Galeotti C, Melki I; Great Paris Region (GPR) Kawa-COVID-19 consortium.

The Course of SARS-COV2 Infection Was Not Severe in a Crohn's Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection

Okeke F, Mone A, Swaminath A.

IBD patients with COVID-19: the picture is taking shape

Papa A, Lopetuso LR, Tursi A.

Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al' by Cheng and Zhang

Della-Torre E, Landoni G, Zangrillo A, Dagna L.

High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab

Conticini E, Franchi F, Bennett D, Valente S, Mazzei MA, Bargagli E, Volterrani L, Scolletta S, Frediani B.

Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al

Ramiro S, Mostard R, Landewé RB.

Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity'

Giollo A, Bixio R, Gatti D, Viapiana O, Idolazzi L, Dejaco C, Rossini M.

Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al

Cheng C, Zhang F.

Correspondence to: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al

Flood RM, Conway R, Kirby C, Gheta D, Kane DJ, Mullan RH.

Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab

Messina F, Pampaloni F, Piaserico S.

Rheumatic diseases and COVID-19: a cohort of 17 patients under DMARDs. Response to: 'Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al

Duret PM, Spielmann L, Messer L.

Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy

Piaserico S, Gisondi P, Cazzaniga S, Naldi L.

Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures

Taxonera C, Alba C, Olivares D, Martin M, Ventero A, Cañas M.

Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre

Zingone F, Buda A, Savarino E.

Virtual rheumatology appointments during the COVID-19 pandemic: an international survey of perspectives of patients with rheumatic diseases

Howren A, Aviña-Zubieta JA, Rebić N, Dau H, Gastonguay L, Shojania K, Davidson E, De Vera MA.

Walk at least 10 minutes a day for adults with knee OA: Recommendation for minimal activity during the COVID-19 pandemic

Jakiela JT, Waugh EJ, White DK.

Risk of COVID-19 in celiac disease patients

Zingone F, D'Odorico A, Lorenzon G, Marsilio I, Farinati F, Savarino EV.

COVID-19 and how evidence of a new disease evolves

Kroon FPB, Mikuls TR, Landewé RB.

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study

Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández Fernández D, Mera-Varela A, Manrique-Arija S, Mena Vázquez N, Fernandez-Nebro A; RIER Investigators Group; RIER investigators group.

COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance phys

Gianfrancesco M, Hyrich KL, Yazdany J, Machado PM, Robinson PC.

Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes

Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, Álvaro-Gracia J.

The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice

Liew JW, Bhana S, Costello W, Hausmann JS, Machado PM, Robinson PC, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Grainger R.

Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic

Chuah SL, Teh CL, Wan Mohd Akbar SA, Cheong YK, Sachdev Manjit Singh B.

Guttate psoriasis secondary to COVID-19

Gananandan K, Sacks B, Ewing I.

Severe COVID-19 outcomes in patients with psoriasis

Lima XT, Cueva MA, Lopes EM, Alora MB.

Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey

Dyrberg Loft N, Halling AS, Iversen L, Vestergaard C, Deleuran M, Rasmussen MK, Zachariae C, Thyssen JP, Skov L.

IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False?

Baradaran Ghavami SH, Shahrokh SH, Hossein-Khannazer N, Shpichka A, Asadzadeh Aghdaei H, Timashev P, Vosough M.

Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?

Kabeerdoss J, Danda D.

Systematic review on IBD patients with COVID-19: it is time to take stock

D'Amico F, Danese S, Peyrin-Biroulet L.

Impact of the COVID-19 lockdown on the management and control of patients with GCA

Praliaud R, Greigert H, Samson M, Zeller M, Boulin M, Bielefeld P, Ramon A, Cottin Y, Bonnotte B.

Impact of lockdown on rheumatology outpatient care in the age of COVID-19

Sachdev Manjit Singh B, Chuah SL, Cheong YK, Wan SA, Teh CL.

Correspondence on 'Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef et al

Lo CH, Wang YH, Tsai CF, Chan KC, Li LC, Lo TH, Su CH, Wei JC.

Mild COVID-19 in ANCA-associated vasculitis treated with rituximab

Suárez-Díaz S, Morán-Castaño C, Coto-Hernández R, Mozo-Avellaneda L, Suárez-Cuervo C, Caminal-Montero L.

Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic

Lecler A, Villeneuve D, Vignal C, Sené T.

Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L.

Response to: 'Correspondence on 'Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef et al' by Lo et al

Duarte-García A, Graef ER, Liew JW, Konig MF, Kim AH, Sparks JA.

Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic

Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV.

Correspondence on: 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al

Pino R, Izurieta AC, Ríos-Barnés M, Ricart S, De Sevilla MF, Monfort L, Launes C, Cano I, Lecina L, Sánchez Manubens J, Mosquera JM, Jordan I, Sánchez de Toledo J, Monsonís M, Esteva C, Muñoz-Almagro C, Fumadó V, Fortuny C, Garcia Garcia JJ, Noguera-Julian A, Anton J; Kids Corona Project.

Hydroxychloroquin ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis

Singer ME, Kaelber DC, Antonelli MJ.

Response to: 'Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future' by Wang et al

Lamb JA, Megremis S, Chinoy H.

Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al' by Pino et al

Ouldali N, Pouletty M, Lokmer J, Benzouid C, Beyler C, Deho A, Meinzer U, Faye A, Melki I; Great Paris Region (GPR) Kawa-COVID-19 consortium.

Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future

Wang Y, Du G, Zhang G, Matucci-Cerinic M, Furst DE.

SARS CoV-2 infection among patients using immunomodulatory therapies

Winthrop KL, Brunton AE, Beekmann S, Polgreen P, Baddley J, Saag KG, Calabrese C, Calabrese L, Robinson PC, Wallace ZS, Curtis JR; COVID-19 Study Team.

Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al

Ugarte-Gil MF, Konig MF, Korsten P, Berenbaum F, Kim AH, Sparks JA.

COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs

Ansarin K, Taghizadieh A, Safiri S, Malek Mahdavi A, Ranjbar S, Teymouri S, Ahangari Maleki M, Khabbazi A.

Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus

Kondo Y, Kaneko Y, Oshige T, Fukui H, Saito S, Okayama M, Kamata H, Ishii M, Hasegawa N, Fukunaga K, Takeuchi T.

Response to: 'Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo et al

Mathian A, Amoura Z.

Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis

Ladda M, Lynde C, Fleming P.

[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020]

Schulze-Koops H, Iking-Konert C, Leipe J, Hoyer BF, Holle J, Moosig F, Aries P, Burmester G, Fiehn C, Krause A, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wagner U, Krüger K, Specker C; Kommission Pharmakotherapie; Vorstand der Deutschen Gesellschaft für Rheumatologie.

Response to: 'Presence of anti-phospholipid antibodies in COVID-19: a case series study' by Amezcua-Guerra et al

Mathian A, Pineton De Chambrun M, Combes A, Amoura Z.

Presence of antiphospholipid antibodies in COVID-19: case series study

Amezcua-Guerra LM, Rojas-Velasco G, Brianza-Padilla M, Vázquez-Rangel A, Márquez-Velasco R, Baranda-Tovar F, Springall R, Gonzalez-Pacheco H, Juárez-Vicuña Y, Tavera-Alonso C, Sanchez-Muñoz F, Hernández-Salas M.

Transient monoarthritis and psoriatic skin lesions following COVID-19

De Stefano L, Rossi S, Montecucco C, Bugatti S.

Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothes

Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A.

To immunosuppress: whom, when and how? That is the question with COVID-19

Winthrop KL, Mariette X.

Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19

Koker O, Demirkan FG, Kayaalp G, Cakmak F, Tanatar A, Karadag SG, Sonmez HE, Omeroglu R, Aktay Ayaz N.

Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis

Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, Danila MI, Korsten P, Sanchez-Alvarez C, Sparks JA, Coates LC, Palmerlee C, Peirce A, Jayatilleke A, Johnson SR, Kilian A, Liew J, Prokop LJ, Murad MH, Grainger R, Wallace ZS, Duarte-García A; COVID-19 Global Rheumatology Alliance.

Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic

Horrigan JM, Siegel CA, Tadros M.

Inflammatory Bowel Disease Management in a Major Referral Center During COVID-19 Pandemic

Garrido I, Lopes S, Macedo G.

Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

Capecchi PL, Lazzerini PE.

COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine

Teh CL, Cheong YK, Wan Musa WR, Wan Mohd Akbar SA, Mat Husin N, Gun SC.

Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al

Mathian A, Amoura Z.

Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G.

More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia

Ferraccioli G.

Rational use of tocilizumab in COVID-19

Jain S, Sharma SK.

Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli

Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Ciceri F, Zangrillo A, Dagna L.

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K; PSO-BIO-COVID study group.

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2

Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, Chatham W, Cohen S, Costenbader K, Gravallese EM, Kalil AC, Weinblatt ME, Winthrop K, Mudano AS, Turner A, Saag KG.

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

Merrill JT, Erkan D, Winakur J, James JA.

COVID-19 in a Patient With Rheumatoid Arthritis During Tocilizumab Treatment

Yamada Z, Nanki T.

Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, Bertasi V, Bianchi M, Bottone D, Civelli P, Cotelli MS, Damiolini E, Galbassini G, Gatta D, Ghirardelli ML, Magri R, Malamani P, Mendeni M, Molinari S, Morotti A, Salada L, Turla M, Vender A, Tincani A, Brucato A, Franceschini F, Furloni R, Andreoli L.

Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation pr

Khan A, Cole A, Bhadauria N, El-Hassan M, Abdulla D, Axon T, Fattah Z, Manson JJ, Moreno-Cuesta J, Mukerjee D.

Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al

Andreica I, Kiefer D, Rezniczek GA, Jast R, Buehring B, Kiltz U, Baraliakos X, Braun J.

COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes

Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, Lesser R, Solomon G, Niemann AL, Blank RB, Izmirly P, Webster DE, Ogdie A, Troxel AB, Adhikari S, Scher JU; NYU WARCOV Investigators.

Virtual Rheumatology During COVID-19: A Personal Perspective

Dacre J.

Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review

He F, Luo Q, Lei M, Fan L, Shao X, Hu K, Qin S, Yu N, Cao J, Yang L.

Improving telemedicine and in-person management of rheumatic and autoimmune diseases,during and after COVID-19 pandemic outbreak. Definite need for more Rheumatologists. Response to: 'Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?' by A

Caso F, Del Puente A, Girolimetto N, Tasso M, Caso C, Scarpa R, Costa L.

COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)

Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, Andreoli L, Caporali R, Gerli R, Sebastiani GD, Valesini G, Sinigaglia L.

Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia

Manfredi A, Luppi F, Cassone G, Vacchi C, Salvarani C, Sebastiani M.

Care of the Patient with IBD Requiring Hospitalization During the COVID-19 Pandemic

Allez M, Fleshner P, Gearry R, Lakatos PL, Rubin DT; IOIBD.

Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce

Magro F, Rahier JF, Abeu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L.

Italian IBD Patients Coping With Covid-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-care

Castellini G, Savarese M, Leone S, Previtali E, Armuzzi A, Graffigna G.

Response to "Italian IBD Patients Coping With COVID-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-Care"

Occhipinti V, Sociale OR, Pastorelli L.

Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak

Rimondi A, Tontini GE, Mazza S, Caprioli F, Sangiovanni A, Lampertico P, Vecchi M.

Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology

Mantovani Cardoso E, Hundal J, Feterman D, Magaldi J.

Determinants of COVID-19 disease severity in patients with underlying rheumatic disease

Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP.

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, Gronenschild M, de Kruif MD, van Haren EHJ, van Kraaij T, Leers MPG, Peeters R, Wong DR, Landewé RBM.

Comment on: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al

Karahan S, Cetinkaya A, Aydin K, Aslan Sirakaya H.

COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre

Cleaton N, Raizada S, Barkham N, Venkatachalam S, Sheeran T, Adizie T, Sapkota H, Singh B, Bateman J.

COVID-19 and Behçet's disease: clinical case series

Espinosa G, Araujo O, Amaro S, Bodro M, Moreno PJ, Moreno R, Ugarte A, Cervera R.

Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences

Ruscitti P, Bruno F, Berardicurti O, Acanfora C, Pavlych V, Palumbo P, Conforti A, Carubbi F, Di Cola I, Di Benedetto P, Cipriani P, Grassi D, Masciocchi C, Iagnocco A, Barile A, Giacomelli R.

Alpha-MSH targeted liposomal nanoparticle for imaging in Inflammatory Bowel Disease (IBD)

Medina TP, Damoah C, Benezra M, Will O, Kairemo K, Humbert J, Seben S, Medina OP.

Interleukin-6 in Rheumatoid Arthritis

Franco P, Laura F, Valentina C, Simona A, Gloria A, Eleonora N.

Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients with Systemic Lupus Erythematosus

Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, Scher JU, Guttmann A, Carlucci PM, Deonaraine KK, Golpanian M, Robins K, Chang M, Belmont HM, Buyon JP, Blazer AD, Saxena A, Izmirly PM; NYU WARCOV Investigators.

COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges

Popa IV, Diculescu M, Mihai C, Cijevschi-Prelipcean C, Burlacu A.

Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients

Canziani LM, Trovati S, Brunetta E, Testa A, De Santis M, Bombardieri E, Guidelli G, Albano G, Folci M, Squadroni M, Beretta GD, Ciccarelli M, Castoldi M, Lleo A, Aghemo A, Vernile L, Malesci A, Omodei P, Angelini C, Badalamenti S, Cecconi M, Cremonesi A, Selmi C; Humanitas and Gavazzeni / Castelli COVID-19 Task Forces.

How infodemic during the COVID-19 outbreak influenced common clinical practice in an Outpatient Service of severe psoriasis

Sacchelli L, Evangelista V, Di Altobrando A, Lacava R, Rucci P, Rosa S, Patrizi A, Bardazzi F.

Challenges in delivering rheumatology care during COVID-19 pandemic

Nune A, Iyengar K, Ahmed A, Sapkota H.

COVID-19 and ethnicity: challenges in rheumatology

Kumar K, Dubey S, Samanta A, Bosworth A, Moorthy A.

Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt

Gheita TA, Salem MN, Eesa NN, Khalil NM, Gamal NM, Noor RA, Moshrif AH, Shereef RE, Ismail F, Noshy N, Fawzy RM, Elshebini E, Khalifa I, Saadany HE, Tharwat S, El-Najjar A, Fattah YA, Sallam R, El-Bahnasawy AS, Gharbia O, Hassan E, ElShanawany A, Mohamed EF, Senara S, Ismail M, Nasef SI, Abdalla AM, Elessawi D, Fawzy SM, Alfadl EA, Khalifa A, Abaza NM; ECR COVID19-Study Group.

Comment on Ye et al 'Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China'

Chen XH, Yeh CJ, Mo HY, Wei JCC.

Response to: 'Comment on Ye et al 'Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China'' by Chen et al

Zhong J, Ye C, Cai S, Dong L.

Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia

Wan SA, Teh CL, Sachdev Manjit Singh B, Cheong YK, Chuah SL, Jobli AT.

Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia?

Duran E, Kilic L, Durhan G, Inkaya AÇ, Guven GS, Karakaya G, Ariyurek OM, Karadag O.

Response to: 'Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia' by Wan et al

Zhong J, Dong L.

American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1

Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, F Son MB, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ.

American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1

Wahezi DM, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, Jones KB, Laxer RM, Pellet Madan R, Mudano AS, Turner AS, Karp DR, Mehta JJ.

Response to: 'Should patients starting biologics be screened for COVID-19?' by Cardenas-de la Garza et al

Landewé RBM, Schulze-Koops H.

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study

Moreno-Pérez O, Andres M, Leon-Ramirez JM, Sánchez-Payá J, Rodríguez JC, Sánchez R, García-Sevila R, Boix V, Gil J, Merino E.

Anticoagulants and immunosuppressants in COVID-19: Bullets to Defeat MicroCLOTS

Turi S, Nardelli P, Landoni G.

Psoriasis and COVID-19: A narrative review with treatment considerations

Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K, Akdeniz N, Atasoy M, Türsen Ü, Lotti T.

The attitude of Polish rheumatology patients towards telemedicine in the age of the COVID-19 pandemic

Opinc A, Łukasik Z, Makowska J.

COVID-19: a short message to rheumatologists

Leszczyński P.

Treatment discontinuation and rate of disease transmission in psoriasis patients on biologic therapy during the COVID-19 pandemic - A Canadian Multicenter Retrospective Study

Georgakopoulos JR, Mufti A, Vender R, Yeung J.

Immune thrombocytopenia in a patient with COVID-19

Deruelle E, Ben Hadj Salem O, Sep Hieng S, Pichereau C, Outin H, Jamme M.

Safety of Endoscopy in Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic

Navaneethan U, Lourdusamy D, LehnerNoguera V, Shen B.

Immune Thrombocytopenia Purpura Secondary to COVID-19

Bennett J, Brown C, Rouse M, Hoffmann M, Ye Z.

Reflections on rheumatological aspects of COVID-19

Calabrese LH, Calabrese C.

Severe Autoimmune Hemolytic Anemia in COVID-19 İnfection, Safely Treated with Steroids

Hindilerden F, Yonal-Hindilerden I, Akar E, Yesilbag Z, Kart-Yasar K.

Management of Pediatric Rheumatological Diseases During the Outbreak of COVID-19: Our Experience

Sutera D, Mazza F, Pajno GB, Spagnolo A, Gallizzi R.

Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India

Goyal M, Patil P, Pathak H, Santhanam S, Goel A, Sharma V, Pandey A, Gupta N, Jain R, Akerkar S, Das P, Dudam R, Mendiratta N, Pandey BD, Cb M, Singh BK, Kumar S, Nolkha N, Jain S, Jain S, Sharma A, Misra DP.

Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal et al

Mathian A, Amoura Z.

Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia

Hakroush S, Franz J, Larsen J, Korsten P, Winkler MS, Tampe B.

COVID-19 complicated by Hashimoto's thyroiditis

Tee LY, Hajanto S, Rosario BH.

Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment

Shah S, Danda D, Kavadichanda C, Das S, Adarsh MB, Negi VS.

Rheumatic disease management in the Campania region of Italy during the COVID-19 pandemic

Masini F, Gjeloshi K, Ferrara R, Pinotti E, Cuomo G.

Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review

Grange L, Guilpain P, Truchetet ME, Cracowski JL; Société française de pharmacologie et de thérapeutique (SFPT).

Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?

Malickova K, Kratka Z, Luxova S, Bortlik M, Lukas M.

Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic

Haslak F, Yildiz M, Adrovic A, Sahin S, Koker O, Aliyeva A, Barut K, Kasapcopur O.

[Impact of COVID-19 on rheumatological care : A national survey in April 2020]

Freudenberg S, Vossen D.

COVID-19 in patients with rheumatic diseases: what is the real mortality risk?

Marques C, Pinheiro MM, Reis Neto ET, Dantas AT, Ribeiro FM, Melo AKG.

Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al

D'Silva KM, Serling-Boyd N, Wallwork R, Hsu TY, Sparks JA, Wallace ZS.

[Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers]

Autoren; Collaborators:.

Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Aysha AA, Rentsch C, Prentice R, Johnson D, Bryant RV, Ward MG, Costello SP, Lewindon P, Ghaly S, Connor SJ, Begun J, Christensen B.

Social isolation due to the COVID-19 pandemic has led to worse outcomes in females with inflammatory arthritis

Maguire S, O'Shea F.

COVID-19-A theory of autoimmunity to ACE-2

McMillan P, Uhal BD.

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

Vispi M, Corradin T, Peccianti C, Feci L, Casini L, Pisani C, Fabbroni S, Corsetti P, Croatto M, Pellegrino M.

Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: is there a role for Interleukin 17?

Carugno A, Gambini DM, Raponi F, Vezzoli P, Robustelli Test E, Arosio MEG, Callegaro A, Sena P.

Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

Kastritis E, Kitas GD, Vassilopoulos D, Giannopoulos G, Dimopoulos MA, Sfikakis PP.

Rheumatic disease and COVID-19

Liew JW, Graef ER.

Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept

Valentini M, Zmerly H.

Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?

Talamonti M, Tofani L, Bianchi L, Galluzzo M.

Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Mareno et al

Liew JW, Graef ER, Sparks JA, Kim AH.

Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?

Santos-Moreno P, Buitrago-Garcia D, Villarreal L, Aza A, Cabrera M, Rivero W, Rojas-Villarraga A.

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study

Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G.

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab

Morrison AR, Johnson JM, Griebe KM, Jones MC, Stine JJ, Hencken LN, To L, Bianchini ML, Vahia AT, Swiderek J, Ramesh MS, Peters MA, Smith ZR.

The course of Covid 19 in Inflammatory Bowel Disease: protective role of TNF antagonists Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

Cappello M, Busacca A, Guida L.

Basic Immunology may lead to translational therapeutic rationale:: SARS-CoV-2 and Rheumatic Diseases

Gremese E, Ferraccioli ES, Alivernini S, Tolusso B, Ferraccioli G.

Patient´s perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice

Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, Polo-Rodríguez I, Piteiro-Bermejo AB, Herrero-Fernández M, Arévalo-Serrano J, Trasobares-Marugán L, Medina-Montalvo S.

Severe refractory thrombocytopenia in a woman positive for coronavirus disease 2019 with lupus and antiphospholipid syndrome

Hayden A, Vyas-Lahar A, Rella V, Rudinskaya A.

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology

Jessica Chang TY, Pope JE.

Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD

Benucci M, Damiani A, Giannasi G, Li Gobbi F, Quartuccio L, Grossi V, Infantino M, Manfredi M.

COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study

Kasap Cuceoglu M, Batu ED, Bilginer Y, Özen S.

Should patients starting biologics be screened for COVID-19?

Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA.

Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al

Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Giorgi Rossi P.

Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide

Baba H, Kanamori H, Oshima K, Seike I, Niitsuma-Sugaya I, Takei K, Sato Y, Tokuda K, Aoyagi T.

Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019

Yu M, Ye Z, Chen Y, Qin T, Kou J, Tian D, Xiao F.

The Risk of Respiratory Tract Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic

Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM.

THE COURAGE TO RETURN TO EVERYDAY LIFE AT THE TIME OF COVID-19: THE POINT OF VIEW OF INFLAMMATORY BOWEL DISEASE PATIENTS NEEDING ENDOSCOPY

Mocciaro F, Scimeca D, Di Mitri R.

New data emerging on outcomes for patients with COVID-19 and rheumatic diseases

Onuora S.

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L; SARI-RAF Study Group; SARI-RAF Study Group members.

Challenges for Management of Immune Thrombocytopenia during COVID-19 Pandemic

Sahu KK, Siddiqui AD, Rezaei N, Cerny J.

Reply to the Letter to the Editor: The Incidence and Outcomes of COVID-19 in Patients With IBD: A Rapid Review and Meta-Analysis

Burgueño JF, Abreu MT.

Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic

Grossberg LB, Pellish RS, Cheifetz AS, Feuerstein JD.

The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis

Aziz M, Fatima R, Haghbin H, Lee-Smith W, Nawras A.

Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?

Hashash JG, Jabak S, Francis FF, Regueiro M.

COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain

Queiro Silva R, Armesto S, Gonz√°lez Vela C, Naharro Fern√°ndez C, Gonz√°lez-Gay MA.

The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center

Lopetuso LR, Scaldaferri F, Ianiro G, Bibbò S, Settanni CR, Papa A, Armuzzi A, Gasbarrini A, Cammarota G.

Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey

Plüß M, Chehab G, Korsten P.

Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß et al

Mathian A, Amoura Z.

Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin-6 via STAT3 signaling in synovial tissues

Mokuda S, Tokunaga T, Masumoto J, Sugiyama E.

COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic

Akintayo RO, Akpabio A, Kalla A, Dey D, Migowa A, Olaosebikan H, Bahiri R, El Miedany Y, Hadef D, Hamdi W, Oyoo O, Slimani S, Yerima A, Taha Y, Adebajo A, Adelowo O, Tikly M, Ghozlani I, Abdelghani KB, Fouad NA, Mosad D, El Mikkawy D, Abu-Zaid MH, Abdel-Magied RA; COVID-19 African Rheumatology Study Group.

Lupus anticoagulant is frequent in patients with Covid-19: Response to Reply

Harzallah I, Debliquis A, Drénou B.

Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases

Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, Monjo I, Tornero C, Villalba A, Miranda-Carus ME, De Miguel E, Bogas P, Castilla-Plaza A, Bernad-Pineda M, García-Lorenzo E, Rodríguez-Araya T, Balsa A.

Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al

Gianfrancesco M, Hyrich KL, Yazdany J, Machado PM, Robinson PC.

Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis

Györfi AH, Kopp M, May M, Vetter M, Uder M, Kremer AE, Schett G, Harrer T, Distler JHW.

A balanced approach to decision-making in supporting people with IDD in extraordinarily challenging times

Luckasson R, Schalock RL.

Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective

Clough JN, Hill KL, Duff A, Sharma E, Ray S, Mawdsley JE, Anderson S, Irving PM, Samaan MA.

Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review

Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R.

Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al

Monti S, Montecucco C.

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A.

Zero COVID-19 infection in inflammatory bowel disease patients: Findings from National IBD Registries in Hong Kong and Taiwan

Mak JWY, Weng MT, Wei SC, Ng SC.

COVID-19 and rheumatology: is shielding really necessary?

Amani L, Warraich R, Patel N, Tahir H.

Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic

Soy M, Atagündüz P, Atagündüz I, Sucak GT.

Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors

Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, Martínez A, Esteve-Vives J, León-Ramírez JM, Moreno-Perez O, Boix V, Gil J, Merino E, Vela P, Andrés M.

Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments

Gendebien Z, von Frenckell C, Ribbens C, André B, Thys M, Gangolf M, Seidel L, Malaise MG, Malaise O.

Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic

Santos-Moreno P, Chavez-Chavez J, Hernández-Zambrano SM, Rivera-Triana DP, Castiblanco-Montañez RA, Aza A, Buitrago-Garcia D, Villarreal L, Rojas-Villarraga A.

Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al

D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Sparks JA, Wallace ZS.

Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Mendel A, Bernatsky S, Askanase A, Bae SC, Clarke AE, Costedoat-Chalumeau N, Gladman DD, Gordon C, Hanly J, Jacobsen S, Kalunian K, Mak A, Mosca M, Pons-Estel BA, Ruiz-Irastorza G, Urowitz M, Vinet É.

Response to: 'Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic' by Santos-Moreno et al

Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L.

Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view

Rom√£o VC, Cordeiro I, Macieira C, Oliveira-Ramos F, Romeu JC, Rosa CM, Saavedra MJ, Saraiva F, Vieira-Sousa E, Fonseca JE.

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors' reply

Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E.

Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic is not a Responsible Act

Schreiber S, Dignass A, Rogge A, Rubin DT.

An urgent need to institute COVID-19 testing in patients with IBD experiencing flares

Quraishi MN, Cooney R, Brookes MJ, Sharma N.

Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19

Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, Tzioufas AG.

Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak

So H, Szeto CC, Tam LS.

Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So et al

Schulze-Koops H, Specker C, Krueger K.

From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area

Axelrad JE, Malter L, Hong S, Chang S, Bosworth B, Hudesman D.

Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience

Pineda-Sic RA, Galarza-Delgado DA, Serna-Peña G, Castillo-Torres SA, Flores-Alvarado DE, Esquivel-Valerio JA, Hernández-Galarza IJ.

Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al

Schulze-Koops H, Krueger K, Specker C; Kommission Pharmakotherapie of the German Society of Rheumatology.

Adherence of infusible biologics during the time of COVID-19 among patients with Inflammatory Bowel Disease: A nationwide VA cohort study

Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX.

The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey

Seyahi E, Poyraz BC, Sut N, Akdogan S, Hamuryudan V.

Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie et al

Gamboa-Alonso CM, Figueroa-Parra G, Galarza-Delgado DA.

Psoriasis and COVID-19: a multifactorial consideration

Cohen JM, Perez-Chada LM, De Kouchkovsky D, Gehlhausen JR.

Clinical management of psoriasis patients during the COVID-19 pandemic

Chat VS, Uppal SK, Kearns DG, Wu JJ.

A cross-sectional survey on the psychological impact of the COVID-19 pandemic on inflammatory bowel disease patients in Saudi Arabia

Mosli M, Alourfi M, Alamoudi A, Hashim A, Saadah O, Al Sulais E, AlAmeel T, Alharbi O, Bakari S, Meeralam Y, Alshobai S, Alsahafi M, Jawa H, Qari Y.

COVID-19: Overview of Rheumatology Fellows

Garcia-Guillén A, Jeria S, Lobo-Prat D, Sainz L.

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19

Fougerousse AC, Perrussel M, Bécherel PA, Begon E, Pallure V, Zaraa I, Chaby G, Parier J, Kemula M, Mery-Bossard L, Poreaux C, Taieb C, Maccari F, Reguiai Z; GEM Resopso.

Inflammatory Bowel Disease in the COVID-19 Pandemic - the Patients' Perspective

Grunert PC, Reuken PA, Stallhofer J, Teich N, Stallmach A.

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, Ramírez-Santana C, Costanzo A, Ridgway WM, Ansari AA, Gershwin ME, Selmi C, Anaya JM.

A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab

Cai S, Sun W, Li M, Dong L.

COVID-19 revisiting inflammatory pathways of arthritis

Schett G, Manger B, Simon D, Caporali R.

Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al

Rom√£o VC, Cruz-Machado AR, Fonseca JE.

Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients

Favalli EG, De Lucia O, Biggioggero M, Del Papa N, Caporali R.

Challenges and opportunities in telerheumatology in the COVID-19 era. Response to: 'Online management of rheumatoid arthritis during COVID-19 pandemic' by Zhang et al

Figueroa-Parra G, Gamboa-Alonso CM, Galarza-Delgado DA.

''Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece''

Vakirlis AE, Bakirtzi K, Papadimitriou I, Vrani F, Sideris N, Lallas A, Ioannides D, Sotiriou E.

Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab

Facheris P, Valenti M, Pavia G, Gargiulo L, Narcisi A, Costanzo A, Borroni RG.

SEVERE IBD FLARES AND COVID-19: EXPAND THE GASTROENTEROLOGY-SURGERY TEAM TO INCLUDE AN INFECTIOUS DISEASE SPECIALIST

Bezzio C, Saibeni S.

Impact of medication discontinuation on patients with inflammatory bowel disease during the COVID-19 outbreak

Chen J, Peng X, Zhang M, Zhi M.

Prevention of COVID-19 in patients with IBD - Authors' reply

Ding NS, An P, Dong W, Ding Y.

COVID-19 in patients with rheumatological diseases treated with anti-TNF

Brito CA, Paiva JG, Pimentel FN, Guimar√£es RS, Moreira MR.

Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot pot' versus in US 'hot pot': similarity and difference

Zhao J, Pang R, Wu J, Guo Y, Yang Y, Zhang L, Xia X.

Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot pot' versus in US 'hot pot': similarity and difference' by Zhao et al

D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Sparks JA, Wallace ZS.

Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study

Huang Y, Chen Z, Wang Y, Han L, Qin K, Huang W, Huang Y, Wang H, Shen P, Ba X, Lin W, Dong H, Zhang M, Tu S.

Psoriasis and risk of the COVID-19 infection: Is there a role for Angiotensin Converting Enzyme (ACE)?

Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S.

COVID-19 infection associated with autoimmune hemolytic anemia

Capes A, Bailly S, Hantson P, Gerard L, Laterre PF.

[Effectiveness of the contingency plan of the internal inflammatory disease unit before Covid-19 infection.]

Carpio López D, Martínez Pillado M, Salgado Barreira Á, Daponte Angueira S, Díez Lage R, Castro Ortiz E, Fernández Salgado E, Pérez Galindo P, Turnes Vázquez J.

Immune monitoring of a child with autoimmune hepatitis and type 1 diabetes during COVID-19 infection

Yuksel M, Akturk H, Arikan C.

Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations

de León-Rendón JL, Hurtado-Salazar C, Yamamoto-Furusho JK.

Comment on "Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment"

Farabi B, Bhargava S, Goldust M, Atak MF.

Molecular mimicry may explain multi-organ damage in COVID-19

Angileri F, Legare S, Gammazza AM, de Macario EC, Macario AJL, Cappello F.

Covid-19 and autoimmunity

Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, Alijotas-Reig J, Zinserling V, Semenova N, Amital H, Shoenfeld Y.

Cutaneous autoimmune diseases during COVID 19 pandemic

Günther C, Aschoff R, Beissert S.

Targeting the immunology of coronavirus disease-19: synchronization creates symphony

Ahmed S, Anirvan P.

Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, Fernandez-Fernandez D, Fernandez-Gutierrez B, Galindo-Izquierdo M, Gonzalez-Gay MA, Manrique-Arija S, Mena Vázquez N, Mera Varela A, Retuerto M, Seijas-Lopez A.

Inflammatory Bowel Disease and COVID-19-"Preventive" Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic

Schlabitz F, Teich N, Michl P, Walldorf J.

How did COVID-19 pandemic changed the Portuguese rheumatology?

Vieira-Sousa E, Fonseca JE, Santos MJ.

SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience

Furfaro F, Vuitton L, Fiorino G, Koch S, Allocca M, Gilardi D, Zilli A, D'Amico F, Radice S, Chevaux JB, Schaefer M, Chaussade S, Danese S, Peyrin-Biroulet L.

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, Bensaid P, Pichard S, Kouider H, Morelle G, Craiu I, Pondarre C, Deho A, Maroni A, Oualha M, Amoura Z, Haroche J, Chommeloux J, Bajolle F, Beyler C, Bonacorsi S, Carcelain G, Koné-Paut I, Bader-Meunier B, Faye A, Meinzer U, Galeotti C, Melki I.

Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort

Costa L, Tasso M, Scotti N, Mostacciuolo E, Girolimetto N, Foglia F, Del Puente A, Scarpa R, Caso F.

Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al

Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V.

Digital crowdsourcing: unleashing its power in rheumatology

Krusche M, Burmester GR, Knitza J.

SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients

Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, Cozzi G, Depascale R, Zanatta E, Gasparotto M, Benvenuti F, Bindoli S, Gatto M, Felicetti M, Ortolan A, Campaniello D, Larosa M, Lorenzin M, Ramonda R, Sfriso P, Schiavon F, Iaccarino L, Doria A.

Screening for active COVID-19 infection prior to biologic therapy in IBD patients: Let's not increase our uncertainty without reducing our concerns

Festa S, Aratari A, De Biasio F, Fascì-Spurio F, Papi C.

Fecal Calprotectin and RT-PCR from both nasopharyngeal swab and stool samples prior to treatment decision in IBD patients during CoVID-19 outbreak

Younes C.

Perspectives of patients with rheumatic diseases in the early phase of COVID-19

Antony A, Connelly K, De Silva T, Eades L, Tillett W, Ayoub S, Morand E.

COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy

Filippi F, Loi C, Evangelista V, Bardazzi F.

Biologics, spondylitis and COVID-19

Rosenbaum JT, Hamilton H, Choi D, Weisman MH, Reveille JD, Winthrop KL.

Covid-19 and inflammatory bowel disease: questions on incidence, severity, and impact of treatment?

Caron B, Arondel Y, Reimund JM.

Risk of Severe COVID-19 in Patients with Inflammatory Bowel Disease in United States. A Multicenter Research Network Study

Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K.

Managing Psoriasis Consultations During the COVID-19 Pandemic: Recommendations from the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (AEDV)

Belinchón I, Puig L, Ferrándiz L, De La Cueva P, Carrascosa JM; en nombre del Grupo de Psoriasis de la AEDV.

Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD

Sebastian S, Gonzalez HA, Peyrin-Biroulet L.

Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic

Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV.

A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor

Beccuti G, Ghizzoni L, Cambria V, Codullo V, Sacchi P, Lovati E, Mongodi S, Iotti GA, Mojoli F.

Rheumatologists rapidly adjust patient care during COVID-19 pandemic

Kirby T.

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

Dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, Ferreira GA, Marques CDL, da Mota LMH, Dos Santos Paiva E, Pileggi GCS, Sato EI, Reis APMG, Xavier RM, Provenza JR.

Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate

Wolf DC, Wolf CH, Rubin DT.

[The treatment of inflammatory bowel disease during the SARS-CoV-2 epidemic – practical advices: (A COVID–19-pandémia orvosszakmai kérdései)]

Resál T, Rutka M, Szántó K, Farkas K, Molnár T.

Covid-19: Was Rheumapatienten jetzt wissen sollten : Handlungsempfehlungen der DGRh

Kraus D.

Management of pediatric rheumatic patients in Kazakhstan during the coronavirus disease 2019 (COVID-19) pandemic

Mukusheva Z, Assylbekova M, Poddighe D.

Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID-19 pandemic

Ling KL, Hilmi I, Raja Ali RA, Leong RWL, Leung WK, Ng SC, Wu KC, Chen MH, Ran ZH, Hisamatsu T, Ahuja V, Makharia GK, Banerjee R, Wei SC, Wu DC, Pisespongsa P, Ye BD, Sollano J, Simadibrata M, Chuah SW, Ooi CJ.

Rheumatologists and Pulmonologists at Temple University weather the COVID-19 storm together

Caricchio R, Criner GJ.

Teamwork, A Novel Concept During an Infectious Pandemic?

Cron RQ, Chatham WW.

Response to: 'Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak' by Holubar et al

Mathian A, Amoura Z.

Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak

Holubar J, Le Quintrec M, Letaief H, Faillie JL, Pers YM, Jorgensen C.

COVID-19 in rheumatic disease patients on immunosuppressive agents

Sharmeen S, Elghawy A, Zarlasht F, Yao QP.

Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients

Sawalha AH, Zhao M, Coit P, Lu Q.

Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation

Woodruff M, Ramonell R, Cashman K, Nguyen D, Ley A, Kyu S, Saini A, Haddad N, Chen W, Howell JC, Ozturk T, Lee S, Estrada J, Morrison-Porter A, Derrico A, Anam F, Wu H, Le S, Jenks S, Hu W, Lee FE, Sanz I.

Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's disease

Potdar AA, Dube S, Naito T, Botwin G, Haritunians T, Li D, Yang S, Bilsborough J, Denson LA, Daly M, Targan SR, Fleshner P, Braun J, Kugathasan S, Stappenbeck TS, McGovern DPB.

COVID-19 and Its Potential Effect on Patients With Rheumatic Diseases in Latin America

Elera-Fitzcarrald C, Ugarte-Gil MF, Alarcón GS.

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

Galluzzo M, Tofani L, Bianchi L, Talamonti M.

Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?

Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C.

Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy

Vezzoli P, Di Mercurio M, Carugno A, Gambini DM, Robustelli Test E, Imberti G, Castagna AF, Sena P.

Adopting PROs in virtual and outpatient management of RA

Taylor PC.

COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases

López-Medina C, Escudero A, Collantes-Estevez E.

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, Gomez-Reino J, Alvaro-Gracia JM; BIOBADASER study group.

Telemedicine: a useful tool but not the holy grail. Response to: 'Telemedicine will not keep us apart in the COVID-19 pandemic' by Perniola et al

Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L.

Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak

Monti S, Montecucco C.

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, Combe B, Galli M, Gossec L, Iagnocco A, Isaacs JD, Mariette X, McInnes I, Mueller-Ladner U, Openshaw P, Smolen JS, Stamm TA, Wiek D, Schulze-Koops H.

COVID-19 infection in a patient with FMF: does colchicine have a protective effect?

Kobak S.

Telemedicine will not keep us apart in COVID-19 pandemic

Perniola S, Alivernini S, Varriano V, Paglionico A, Tanti G, Rubortone P, Lanzo L, Melpignano F, Tur C, De Lorenzis E, Peluso G, Capacci A, Gremese E.

Response to: 'COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina et al

Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L.

Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab

Avouac J, Airó P, Carlier N, Matucci-Cerinic M, Allanore Y.

Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al

Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, Jung B, Larcher R, Klouche K, Le Moing V.

The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis

Liu M, Gao Y, Zhang Y, Shi S, Chen Y, Tian J.

Rheumatic diseases during pregnancy and SARS-CoV-2: An appeal for medication adherence

Scioscia M, Praino E, Scioscia C.

Psoriasis-COVID 19 Infection: Treatment Options

Tampouratzi E, Kanni T, Katsantonis J, Douvali T.

Implications of COVID-19 in pediatric rheumatology

Batu ED, Özen S.

Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-a case report

Hu Z, Chen W, Liang W, Xu C, Sun W, Yi Y.

Autoimmune and inflammatory diseases following COVID-19

Galeotti C, Bayry J.

Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report

Papamichalis P, Papadogoulas A, Katsiafylloudis P, Skoura AL, Papamichalis M, Neou E, Papadopoulos D, Karagiannis S, Zafeiridis T, Babalis D, Komnos A.

Author´s answer to: "Effect of adacolumn® in ulcerative colitis with COVID-19"

Hinojosa Del Val J, Crespo J, Pérez-Cuadrado Martínez E.

The effect of Adacolumn® on ulcerative colitis with COVID-19

Pérez Roldán F, Bernardos Martín ME, González Carro P.

Recommendations for Treatment of Nail Psoriasis During the COVID-19 Pandemic

Ricardo JW, Lipner SR.

Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

Martin Arranz E, Suarez Ferrer C, García Ramírez L, Rueda García JL, Sánchez-Azofra M, Poza Cordón J, Noci J, Zabana Y, Barreiro-de Acosta M, Martín-Arranz MD.

COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation

Wahlster L, Weichert-Leahey N, Trissal M, Grace RF, Sankaran VG.

COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy

Benoy S, Traksel R, Verhaegh P, Broen J.

Self-care recommendations for patients with rheumatic diseases during the COVID-19 pandemic

Kim HS, Lee MS, Kim H, Sung YK, Lee J, Shim SC, Park SH, Baek HJ.

Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity

Costello F, Dalakas MC.

The day after COVID-19 in IBD: how to go back to 'normal'

Danese S, Sands B, Ng SC, Peyrin-Biroulet L.

Are patients with systemic lupus erythematosus at increased risk of severe COVID-19?

Favalli EG, Agape E, Caporali R.

No SLE with COVID-19 in Hong Kong: the effect of masking?

So H, Mak JWY, Tam LS.

Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?

Del Hoyo J, Aguas M.

Rates of symptomatic SARS-CoV-2 infection in patients with autoimmune liver diseases in Northern Italy: a telemedicine study

Rigamonti C, Cittone MG, De Benedittis C, Rizzi E, Casciaro GF, Bellan M, Sainaghi PP, Pirisi M.

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease

Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS; JRC Study Group; WCM-GI Study Group.

Psoriatic Arthritis and COVID-19 Pandemic: Consequences in Medical Treatment?

Wollina U, Fioranelli M, Goldust M, Lotti T.

Covid-19 infection in psoriasis patients treated with cyclosporin

Di Lernia V, Goldust M, Feliciani C.

Psoriasis, biologic therapy, and the pandemic of the 21st century

Nogueira M, Vender R, Torres T.

Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report

Lee JM, Lee SJ.

The Greek Response to COVID-19: A True Success Story from an IBD Perspective

Bamias G, Lagou S, Gizis M, Karampekos G, Kyriakoulis KG, Pontas C, Mantzaris GJ.

Patients with lupus with COVID-19: University of Michigan experience

Wallace B, Washer L, Marder W, Kahlenberg JM.

Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic

Konig MF, Gianfrancesco M, Yazdany J, Robinson PC.

No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al

Schulze-Koops H, Krueger K, Specker C.

Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al

Mathian A, Amoura Z.

Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Carbillon L, Benbara A, Boujenah J.

Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic

Fragoulis GE, Evangelatos G, Arida A, Bournia VK, Fragiadaki K, Karamanakos A, Kravvariti E, Laskari K, Panopoulos S, Pappa M, Tektonidou MG, Sfikakis PP.

Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto

Georgakopoulos JR, Yeung J.

Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice

Chen Y, Yu Q, Farraye FA, Kochhar GS, Bernstein CN, Navaneethan U, Wu K, Zhong J, Schwartz DA, Wu H, Zheng JJ, Iacucci M, Kiran RP, Shen B.

Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment

Magnano M, Balestri R, Bardazzi F, Mazzatenta C, Girardelli CR, Rech G.

Potential role of Anti-IL-17 in COVID-19 treatment

Ayhan E, Öztürk M, An İ, Abdelmaksoud A, Araç E.

Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic

Melis D, Mugheddu C, Sanna S, Atzori L, Rongioletti F.

Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab

Valenti M, Facheris P, Pavia G, Gargiulo L, Borroni RG, Costanzo A, Narcisi A.

Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?

Vakil-Gilani K, O'Rourke K.

Switching to teleconsultation for rheumatology in the wake of the COVID-19 pandemic: feasibility and patient response in India

Shenoy P, Ahmed S, Paul A, Skaria TG, Joby J, Alias B.

Innovation in IBD Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease

Lees CW, Regueiro M, Mahadevan U; International Organization for the Study of Inflammatory Bowel Disease.

Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient

Sagnelli C, Gentile V, Tirri R, Macera M, Cappabianca S, Ciccia F; Vanvitelli COVID-19 group.

Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020

Richez C, Flipo RM, Berenbaum F, Cantagrel A, Claudepierre P, Debiais F, Dieudé P, Goupille P, Roux C, Schaeverbeke T, Wendling D, Pham T, Thomas T.

COVID 19 and Ethnicity: Spot light on the global rheumatology issues in developing and developed countries

Moorthy A, Dubey S, Samanta A, Adebajo A, Aggarwal A, Jain A, Jain N, Lim SS, Kerr GS, Kumar K.

Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFα antibodies: a case report

Kunisaki R, Tsukiji J, Kudo M.

Rheumatology Care in the Face of COVID-19

Lubrano E, Scriffignano S, Perrotta FM.

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments

Ouédraogo DD, Tiendrébéogo WJS, Kaboré F, Ntsiba H.

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC; COVID-19 Global Rheumatology Alliance.

Response to: Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour et al

Mathian A, Amoura Z.

Case series of acute arthritis during COVID-19 admission

López-González MD, Peral-Garrido ML, Calabuig I, Tovar-Sugrañes E, Jovani V, Bernabeu P, García-Sevila R, León-Ramírez JM, Moreno-Perez O, Boix V, Gil J, Merino E, Vela P, Andrés M.

Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'

Nikpour M, Teh B, Wicks IP, Pellegrini M.

Response to: 'Case series of acute arthritis in COVID-19 admission' by López-González et al

Graef ER, Liew JW, Kim AH, Sparks JA.

Frequency of lupus anticoagulant in Covid-19 patients

Harzallah I, Debliquis A, Drénou B.

Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.

Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study

Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P.

Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR

Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N, Li M, Lorenzo JP, Song YW, Yamamoto K, Zeng X, Haq SA.

Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19

Albiol N, Awol R, Martino R.

Use of systemic therapies for psoriasis in the COVID-19 era

Kearns DG, Uppal S, Chat VS, Wu JJ.

Considerations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID-19 pandemic

Ricardo JW, Lipner SR.

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'

D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, Choi HK, Sparks JA, Wallace ZS.

Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)

Lagziel T, Quiroga L, Ramos M, Hultman CS, Asif M.

Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab

Dolinger MT, Person H, Smith R, Jarchin L, Pittman N, Dubinsky MC, Lai J.

COVID-19: the new challenge for rheumatologists. First update

Ferro F, Elefante E, Puxeddu I, Baldini C, Bartoloni E, Baratè C, Galimberti S, Talarico R, Mosca M, Bombardieri S.

Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination

Cutolo M, Smith V, Paolino S.

Treating Covid-19 at the Inflection Point

Chatham WW, Cron RQ.

Evidence of protective effect of hydroxychloroquine to prevent COVID-19

Joob B, Wiwanitkit V.

Dr. Balevic, et al, reply

Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, Schanberg LE, Eudy AM, Swamy GK, Hughes BL, Cohen-Wolkowiez M.

Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli et al

Mathian A, Amoura Z.

Are patients with systemic lupus erythematosus at increased risk for COVID-19?

Favalli EG, Gerosa M, Murgo A, Caporali R.

IBD in the Times of COVID-19

Hern√°ndez Benabe S, Langshaw AH.

Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis

Monti S, Delvino P, Bellis E, Milanesi A, Brandolino F, Montecucco C.

YouTube as a source of information on COVID-19 and rheumatic disease link

Kocyigit BF, Akaltun MS, Sahin AR.

Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy

Quartuccio L, Valent F, Pasut E, Tascini C, Vita S.

Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China

Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, Tu W, Chen Y, Yu Y, Wu X, Chen Y, Zhong J, Dong L.

Telemedicine for Pediatric Inflammatory Bowel Disease in the Era of COVID-19

Verstraete SG, Sola AM, Ali SA.

Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition

Turner D, Huang Y, Martín-de-Carpi J, Aloi M, Focht G, Kang B, Zhou Y, Sanchez C, Kappelman MD, Uhlig HH, Pujol-Muncunill G, Ledder O, Lionetti P, Dias JA, Ruemmele FM, Russell RK; Paediatric IBD Porto group of ESPGHAN.

Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment

Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J.

Prevention of COVID-19 in patients with IBD

Segal JP, Quraishi MN, Bhala N, Brookes MJ.

Protecting patients with IBD during the COVID-19 pandemic

Fiorino G, Peyrin-Biroulet L, Danese S.

A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19

Yang Y, Zhao J, Wu J, Teng Y, Xia X.

Should we be using the Covid-19 outbreak to prompt us to transform our rheumatology service delivery in the technology age?

Jethwa H, Abraham S.

Clinical and Psychological Issues in Children with Inflammatory Bowel Disease During COVID-19 Pandemic

Martinelli M, Strisciuglio C, Fedele F, Miele E, Staiano A.

Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience

Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, Wang FS.

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A.

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic

D'Amico F, Peyrin-Biroulet L, Danese S.

Covid-19 and Exacerbation of Psoriasis

Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H.

Response to: 'Hydroxychloroquine shortages during the COVID-19 pandemic' by Mendel et al

McInnes I.

Rheumatic diseases in intensive care unit patients with COVID-19

Moiseev S, Avdeev S, Brovko M, Yavorovskiy A, Novikov PI, Umbetova K, Akulkina L, Tsareva N, Fomin V.

Hydroxychloroquine shortages during the COVID-19 pandemic

Mendel A, Bernatsky S, Thorne JC, Lacaille D, Johnson SR, Vinet É.

Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al

Monti S, Montecucco C.

Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?

Ruscitti P, Berardicurti O, Barile A, Cipriani P, Shoenfeld Y, Iagnocco A, Giacomelli R.

Is Biologic Treatment of Hidradenitis Suppurativa During the COVID-19 Pandemic Different from Psoriasis Biologic Treatment?

Rosi E, Pimpinelli N, Prignano F.

Should coronavirus disease 2019 concern rheumatologists?

Kucharz EJ.

Starting a biologic therapy in IBD patients amidst COVID-19: hold, careful monitoring or testing?

Zingone F, Buda A, Savarino EV.

[Therapeutic options for the management of severe Covid-19: A rheumatology perspective]

Mendoza-Pinto C, García-Carrasco M, Realpozo PM, Méndez-Martínez S.

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Antón S, Añez GA, Caparrós-Ruiz R, Pluma A, Trallero-Araguás E, Barceló-Bru M, Almirall M, De Agustín JJ, Segura JL, Julià A, Marsal S.

Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD.

Roles of Clinical Pharmacists in Caring for Patients with Inflammatory Bowel Disease during COVID-19

Bhat S, Farraye FA, Moss A.

The utility of fecal calprotectin in the era of COVID-19 pandemic

Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast

Armesto S, González Vela C, González López MA.

Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?

Erre GL, Ferraccioli ES, Piga M, Mangoni A, Passiu G, Gremese E, Ferraccioli G.

Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre et al

Graef ER, Liew JW, Kim AH, Sparks JA.

COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?

Jethwa H, Sullivan A, Abraham S.

Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic

Kotze PG, Peyrin-Biroulet L, Danese S.

Management Strategies of Autoimmune bullous diseases during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19).

Chen P, Zhang G, Zhan Y.

Evans syndrome in a patient with COVID-19.

Li M, Nguyen CB, Yeung Z, Sanchez K, Rosen D, Bushan S.

[COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)]

Marín-Jiménez I, Zabana Y, Rodríguez-Lago I, Marín L, Acosta MB, Esteve M; en representación de GETEII y GETECCU.

Implementing Telemedicine in Inflammatory Bowel Disease: is COVID-19 the definitive trigger?

Hoyo JD, Aguas M.

Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

Fortuné C, Gietzen A, Guillot G, Lewis N, Nielsen K, Richard M, Sauvé M, Welling J; SPIN Investigators, Baron M, Furst DE, Gottesman K, Malcarne V, Mayes MD, Mouthon L, Nielson WR, Riggs R, Wigley F, Assassi S, Boutron I, Ells C, van den Ende C, Fligelstone K, Frech T, Godard D, Harel D, Hinchcliff M, Hudson M, Johnson SR, Larche M, Leite C, Nguyen C, Pope J, Portales A, Rannou F, Reyna TSR, Schouffoer AA, Suarez-Almazor ME, Agard C, Albert A, André M, Arsenault G, Benzidia I, Bernstein EJ, B

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic

Wan MT, Shin DB, Winthrop KL, Gelfand JM.

COVID-19 knowledge prevents biologics discontinuation: data from an Italian multi-center survey during RED-ZONE declaration.

Bragazzi NL, Riccò M, Pacifico A, Malagoli P; COVID19 Dermatological Task Force, Young Dermatologists Italian Network., Kridin K, Pigatto P, Damiani G.

Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients

Azzam NA, Aljebreen A, Almuhareb A, Almadi MA.

Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al.

Monti S, Montecucco C.

COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.

Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D'Alessandro R, Cantarini L, Frediani B.

Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.

Health status of patients with Autoimmune Liver Disease during SARS-CoV-2 outbreak in northern Italy.

Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic.

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey.

COVID-19 with rheumatic diseases: a report of 5 cases.

Cheng C, Li C, Zhao T, Yue J, Yang F, Yan Y, Liu X.

COVID-19 and your rheumatology patients.

Calabrese C.

Excessive anxiety in IBD patients is unnecessary for COVID-19.

Keeping on the high quality of healthcare in Greek Inflammatory Bowel Disease patients in the SARS-CoV-2 era.

Could Patients With Inflammatory Bowel Disease Treated with Immunomodulators or Biologics Be at Lower Risk for Severe Forms of Covid-19?

Impact of COVID-19 outbreak on the management of patients with severe IBD: a domino effect.

Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: A web-based survey.

Experience of a second-level Rheumatology Clinic during the Covid-19 quarantine.

Colaci M, Aprile ML, Sambataro D, Sambataro G, Malatino L.

A survey of psoriasis patients on biologics during COVID-19: a single centre experience.

Burlando M, Carmisciano L, Cozzani E, Parodi A.

Tocilizumab: From the Rheumatology Practice to the Fight Against COVID-19, a virus infection with multiple faces.

González-Gay MA, Mayo J, Castañeda S, Cifrián JM, Hernández-Rodríguez J.

Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic.

Benson-Pope SJ, Gearry RB.

Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic-authors' reply.

King DS, Trudgill NJ, Adderley NJ.

COVID-19 with rheumatic diseases: a report of 5 cases.

Cheng C, Li C, Zhao T, Yue J, Yang F, Yan Y, Liu X.

Response to: 'Patients with lupus are not protected from COVID-19: a comment' by Sawalha, 'No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit' by Rom√£o et al and 'SLE patients are not immune to COVID-19: importance of s...

Joob B, Wiwanitkit V.

How to Effectively Support Patients with Rheumatic Conditions Now and Beyond COVID-19.

Décary S, Barton JL, Proulx L, Richards DP, Paterson G, de Wit M, Toupin-April K.

COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine.

Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L.

Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature.

Rosen MH, Axelrad J, Hudesman D, Rubin DT, Chang S.

Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.

Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, Schanberg LE, Eudy AM, Swamy GK, Hughes BL, Cohen-Wolkowiez M.

Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.

Littlejohn E.

COVID-19 in Patients with Myasthenia Gravis.

Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, David WS, Guidon AC.

Inflammatory bowel disease and the SARS-CoV-2 pandemic: more speed, less haste.

COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy.

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California.

Capturing patient-reported outcomes during the COVID-19 pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey.

Sirotich E, Dillingham S, Grainger R, Hausmann JS; COVID-19 Global Rheumatology Alliance Steering Committee..

Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not?

Grassia R, Soro S, Conti CB.

COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.

Mugheddu C, Pizzatti L, Sanna S, Atzori L, Rongioletti F.

Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19.

Tursi A, Vetrone LM, Papa A.

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.

Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, Machado PM, Gianfrancesco M, Yazdany J, Langguth D, Robinson PC; COVID-19 Global Rheumatology Alliance..

Challenges in chronic paediatric disease during the COVID-19 pandemic: diagnosis and management of inflammatory bowel disease in children.

Ashton JJ, Batra A, Coelho TAF, Afzal NA, Beattie RM.

Response to "Lupus anticoagulant is frequent in patients with Covid-19".

Tang N.

Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient.

Benhadou F, Del Marmol V.

Coagulopathy of COVID-19 and antiphospholipid antibodies.

Connell NT, Battinelli EM, Connors JM.

Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.

Conti A, Lasagni C, Bigi L, Pellacani G.

Widening Disparities Among Patients with Rheumatic Diseases in the COVID-19 Era: An Urgent Call to Action.

Feldman CH, Ramsey-Goldman R.

Initial data from the COVID-19 Global Rheumatology Alliance provider registries - Authors' reply.

Initial data from the COVID-19 Global Rheumatology Alliance provider registries.

The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients.

Author Correction: Management of IBD during the COVID-19 outbreak: resetting clinical priorities.

Danese S, Cecconi M, Spinelli A.

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.

Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, Justet A.

Autoimmune hemolytic anemia associated with Covid-19 infection.

Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, Merabet F, Mekinian A, Braun T, Damaj G, Delmer A, Cymbalista F.

COVID-19: an unexpected indication for anti-rheumatic therapies?

Lucchino B, Di Franco M, Conti F.

The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance.

Wallace ZS, Bhana S, Hausmann JS, Robinson PC, Sufka P, Sirotich E, Yazdany J, Grainger R.

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.

Garg M, Royce SG, Lubel JS.

Is it Crohn's disease?

The correlation between SARS-CoV-2 infection and rheumatic disease.

Practical Advice for Management of IBD Patients during the COVID-19 Pandemic: A World Endoscopy Organization Statement.

Neumann H, Emura F, Bokemeyer B, Guda N, Tajiri H, Matsumoto T, Rubin DT.

Simultaneous Onset of COVID-19 and Autoimmune Hemolytic Anemia.

Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG.

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, MacDonald V, Green L, Sivapalaratnam S, Pasi KJ, MacCallum P.

Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology.

Global rheumatology in the time of COVID-19.

Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?

Kutlu Ö, Metin A.

Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis.

Spinelli FR, Ceccarelli F, Di Franco M, Conti F.

A challenging case of psoriasis flare-up after COVID-19 infection.

Going Viral: Management of IBD in the Era of the COVID-19 Pandemic.

Gutin LS, Lam AY, Velayos FS, Santos SA.

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak.

2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases.

Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E.

Comment on "Antipsoriatic treatments during COVID-19 outbreak".

Abdelmaksoud A, Goldust M, Vestita M.

Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.

Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.

Balestri R, Rech G, Girardelli CR.

Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.

Price E, MacPhie E, Kay L, Lanyon P, Griffiths B, Holroyd C, Abhishek A, Youngstein T, Bailey K, Clinch J, Shaikh M, Rivett A.

Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.

Damiani G, Pacifico A, Bragazzi NL, Malagoli P.

What Does the COVID-19 Pandemic Mean for Rheumatology Patients?

Pope JE.

Combating physical inactivity during the COVID-19 pandemic.

Pinto AJ, Dunstan DW, Owen N, Bonf√° E, Gualano B.

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.

Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, et al.

Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al.

Monti S, Montecucco C.

Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al.

Monti S, Montecucco C.

Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.

Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L.

Letter: Gastrointestinal ACE2, COVID-19 and IBD - opportunity in the face of tragedy?

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States.

Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM.

The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia.

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.

Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, de Paulis A, Denton CP, Distler O, Fox D, Furst DE, Khanna D, Krieg T, Kuwana M, Lee EB, Li M, Pillai S, Wang Y, Zeng X, Taliani G.

American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID-19 Pandemic.

Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, Chatham W, Cohen S, Costenbader K, Gravallese EM, Kalil AC, Weinblatt ME, Winthrop K, Mudano AS, Turner A, Saag KG.

Ambulatory Management of perianal Crohn's Disease during the Covid-19 Pandemic.

Andrea D, Bruno S, Giuseppe S.

Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient.

Al-Ani A, Prentice R, Rentsch C, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae F, Ng SC, Rubin DT, Christensen B.

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.

Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; et al.

[Rheumatology and COVID-19].

Dumusc A, Dan D.

[Autoimmune diseases in the context of pandemic COVID-19].

Horisberger A, Moi L, Ribi C, Comte D.

Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/Covid-19 pandemic.

Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K.

Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.

Spinelli FR, Ceccarelli F, Di Franco M, Conti F.

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey.

Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L.

Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.

Moutsopoulos HM.

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.

Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, Cazzaniga S, Malagoli P, Costanzo A.

[Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic].

Schulze-Koops H, Holle J, Moosig F, Specker C, Aries P, Burmester G, Fiehn C, Hoyer B, Krause A, Leipe J, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wager U, Krüger K, Iking-Konert C; im Auftrag der Kommission Pharmakotherapie und des Vorstandes der Deutschen Gesellschaft für Rheumatologie..

Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib.

Jacobs J, Clark-Snustad K, Lee S.

Managing patients with rheumatic conditions during the covid-19 pandemic.

Caporali R, Favalli EG.

Online management of rheumatoid arthritis during COVID-19 pandemic.

Zhang Y, Wang J, Zhao L, Xiao J, Shi Z.

The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?...

Monti S, Montecucco C.

Biologics for psoriasis in COVID-19 era: what do we know?

Megna M, Napolitano M, Patruno C, Fabbrocini G.

Rheumotologitsts' View on the Use of Hydroxychloroquine to Treat COVID-19.

Sun X, Ni Y, Zhang M.

The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.

Cron RQ, Chatham WW.

Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.

Favalli EG, Agape E, Caporali R.

Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.

Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R; Pediatric Rheumatology Group of the Milan Area..

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.

Kasperkiewicz M, Schmidt E, Fairley JA, Joly P, Payne AS, Yale ML, Zillikens D, Woodley DT.

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.

Burgueño JF, Reich A, Hazime H, Quintero MA, Irina F, Fritsch J, Santander AM, Brito N, Damas OM, Deshpande A, Kerman DH, Zhang L, Gao Z, Ban Y, Wang L, Pignac-Kobinger J, Abreu MT.

Patients with lupus are not protected from COVID-19.

Sawalha AH.

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.

Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, Devaux M, Euvrard R, Fadlallah J, Florens N, Haroche J, Hié M, Juillard L, Lhote R, Maillet T, Richard-Colmant G, Palluy JB, Pha M, et al.

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.

Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G.

Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain).

Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, Merino O, Ortiz de Zárate J, Cabriada JL.

COVID-19, osteoarthritis and women's health.

Mobasheri A.

Translating IL-6 biology into effective treatments.

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T.

Management of inflammatory bowel disease during COVID-19 pandemic.

Ribaldone DG, Astegiano M, Actis GC, Pellicano R.

Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.

Monti S, Montecucco C.

Myositis as a manifestation of SARS-CoV-2.

Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre AS, Thomas M, Herrou J, Riviere E, Mariette X.

SLE patients are not immune to covid-19: importance of sending the right message across.

Goyal M.

Lupus anticoagulant is frequent in patients with Covid-19.

Harzallah I, Debliquis A, Drénou B.

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Favalli EG, Ingegnoli F, Cimaz R, Caporali R.

To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.

Parperis K.

Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).

Giollo A, Adami G, Gatti D, Idolazzi L, Rossini M.

Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases.

Richez C, Lazaro E, Lemoine M, Truchetet ME, Schaeverbeke T.

COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.

Licciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R.

Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance.

Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Dami√£o AOMC.

Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?

Xie W, Wang Y, Zhang Z.

Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?

Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V.

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.

Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli R.

Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19.

Zhou Y, Han T, Chen J, Hou C, Hua L, He S, Guo Y, Zhang S, Wang Y, Yuan J, Zhao C, Zhang J, Jia Q, Zuo X, Li J, Wang L, Cao Q, Jia E.

Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a "Red Zone" Area in Northern Italy.

Occhipinti V, Pastorelli L.

COVID-19 and psoriasis : should we fear for patients treated with biologics?

Amerio P, Prignano F, Giuliani F, Gualdi G.

Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.

Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, Lim DH.

Faecal calprotectin indicates intestinal inflammation in COVID-19.

Effenberger M, Grabherr F, Mayr L, Schwaerzler J, Nairz M, Seifert M, Hilbe R, Seiwald S, Scholl-Buergi S, Fritsche G, Bellmann-Weiler R, Weiss G, Müller T, Adolph TE, Tilg H.

Covid-19 infection in Crohn's disease under treatment with adalimumab.

Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, Papa A.

Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.

Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, Jung B, Larcher R, Klouche K, Le Moing V.

Experiences of Patients with Rheumatic Diseases in the US During Early Days of the COVID-19 Pandemic.

Michaud K, Wipfler K, Shaw Y, Simon TA, Cornish A, England BR, Ogdie A, Katz P.

Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China.

An P, Ji M, Ren H, Su J, Ding NS, Kang J, Yin A, Zhou Q, Shen L, Zhao L, Jiang X, Xiao Y, Tan W, Lv X, Li J, Liu S, Zhou J, Chen H, Xu Y, Liu J, Chen M, Cao J, et al.

Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.

Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J; COVID-19 Global Rheumatology Alliance Steering Committee..

Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community.

The Lancet Rheumatology.

Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic.

Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F.

Inflammatory bowel diseases and COVID-19: the invisible enemy.

D'Amico F, Peyrin-Biroulet L, Danese S.

Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.

Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B.

Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic.

Allocca M, Fiorino G, Furfaro F, Gilardi D, Radice S, D'Amico F, Zilli A, Danese S.

[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].

Schmeiser T, Broll M, Dormann A, Fräbel C, Hermann W, Hudowenz O, Keil F, Müller-Ladner U, Özden F, Pfeiffer U, Saech J, Schwarting A, Stapfer G, Steinchen N, Storck-Müller K, Strunk J, Thiele A, Triantafyllias K, Wassenberg S, Wilden E, Hasseli R.

Impact of anti-tnfα antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases.

Tursi A, Papa A.

Will COVID-19 infection be less severe in ulcerative colitis than in Crohn's patients due to a lower rate of smokers?

Peyrin-Biroulet C, D'Amico F, Peyrin-Biroulet L.

Covid-19 and immunomodulation in IBD.

Neurath MF.

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.

Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, et al.

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.

Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, Wu D, Chen F, Sun J, Chang C.

Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?

Di Altobrando A, Patrizi A, Bardazzi F.

Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears.

Megna M, Ruggiero A, Marasca C, Fabbrocini G.

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.

Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.

COVID-19 and rheumatology: first steps towards a different future?

McInnes IB.

Antirheumatic agents in covid-19: is IL-6 the right target?

Capecchi PL, Lazzerini PE, Volterrani L, Mazzei MA, Rossetti B, Zanelli G, Bennett D, Bargagli E, Franchi F, Cameli M, Valente S, Cantarini L, Frediani B.

Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India.

Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V.

COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs.

Tufan A, Avanoğlu Güler A, Matucci-Cerinic M.

Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy.

Costi S, Caporali R, Cimaz R.

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.

Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.

Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19.

Lu C, Li S, Liu Y.

Does hydroxychloroquine prevent the transmission of covid-19?

Heldwein FL, Calado A.

SLE, hydroxychloroquine and no SLE patients with covid-19: a comment.

Joob B, Wiwanitkit V.

Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist.

Graef ER, Liew JW, Putman MS, Simard JF, Sirotich E, Berenbaum F, Duarte-García A, Grainger R, Harrison C, Konig MF, Korsten P, Proulx L, Richards DP, Robinson PC, Sattui SE, Ugarte-Gil MF, Young KJ, Kim AH, Sparks JA; COVID-19 Global Rheumatology Alliance..

Immune Thrombocytopenic Purpura in a Patient with Covid-19.

Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E.

Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in sardinia (Italy).

Atzori L, Mugheddu C, Addis G, Sanna S, Satta R, Ferreli C, Atzori MG, Montesu MA, Rongioletti F.

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.

Messina F, Piaserico S.

Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management.

Bodini G, Demarzo MG, Casagrande E, De Maria C, Kayali S, Ziola S, Giannini EG.

Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity.

Lyons-Weiler J.

Psoriasis and Psoriatic Arthritis: how to manage Immunosuppressants in COVID-19‚Äâdays.

Coletto LA, Favalli EG, Caporali R.

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Liu B, Li M, Zhou Z, Guan X, Xiang Y.

COVID-19 - Considerations for the paediatric rheumatologist.

Hedrich CM.

Reply to: "Biologics for psoriasis during COVID-19 outbreak".

Biologics for psoriasis during COVID-19 outbreak.

Di Lernia V.

COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution

.

Adalimumab for Treatment of Hidradenitis Suppurativa During the COVID-19 Pandemic: Safety Considerations.

Blaszczak A, Trinidad JCL, Cartron AM.

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.

Rubin DT, Feuerstein JD, Wang AY, Cohen RD.

Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab.

De Luna G, Habibi A, Deux JF, Colard M, d'Alexandry d'Orengiani ALPH, Schlemmer F, Joher N, Kassasseya C, Pawlotsky JM, Ourghanlian C, Michel M, Mekontso-Dessap A, Bartolucci P.

Telemedicine for Pediatric Inflammatory bowel disease in the Era of COVID-19.

Verstraete SG, Sola AM, Ali SA.

A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).

Shah S, Das S, Jain A, Misra DP, Negi VS.

Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.

Misra DP, Agarwal V, Gasparyan AY, Zimba O.

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.

Torres T, Puig L.

Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.

Sawalha AH, Zhao M, Coit P, Lu Q.

Stand Together and Deliver: Challenges and Opportunities for Rheumatology Education During the COVID-19 Pandemic.